Novel metabolic imaging markers to track IDH-mutant glioma response
Official title: Project 2: Novel hyperpolarized C-13 imaging as metabolic markers of response in IDH mutant glioma
Funded at University of California, San Francisco · NIH-11399845 · Data updated 2026-11-12
A patient-friendly look at using advanced hyperpolarized carbon imaging to see how IDH-mutant brain tumors respond to treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 20, 2002 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $422,459 |
| NIH project number | 5P50CA097257-24 |
| Project ID | NIH-11399845 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with IDH-mutant glioma who are undergoing treatment or evaluation for therapy.
✕Less likely to help
Patients with tumors not suitable for hyperpolarized imaging or without IDH mutation may not benefit.
What this research studies
This project uses cutting-edge metabolic imaging to visualize how IDH-mutant gliomas change with treatment, potentially showing earlier signs of response than standard scans. It builds on prior work with hyperpolarized carbon imaging to measure tumor metabolism in real time. By comparing metabolic markers to tumor behavior, doctors may better tailor treatment for adults with this brain cancer.
Why it matters
Potential benefit: If successful, this approach could provide earlier and clearer indications of treatment response, helping patients receive timely and appropriate therapies.
How similar studies have gone: Previous studies in glioblastoma show metabolic imaging can reveal tumor activity and response; this extends similar methods to IDH-mutant gliomas.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Chang, Susan M — University of California, San Francisco
- Study coordinator: Chang, Susan M
Related research
Other NIH-funded projects on the same topics.
-
Next‑gen oncolytic virus therapy for glioblastoma targeting AKT and ERK
A new cancer therapy using an engineered oncolytic virus to fight glioblastoma by blocking AKT/ERK signals and boosting the body’s immune response, with potential to reduce seizures and improve quality of life.
-
Bone marrow immune cells and glioma progression in teens and young adults
A study in adolescents and young adults with brain tumors looks at how immune cells from bone marrow may influence the progression from low-grade to high-grade gliomas.
-
How RNA Splicing Might Shape Glioma Cell States and Therapy Response
A small NIH-funded project will study how alternative RNA splicing influences glioma cell identities and treatment resistance in patient-derived cells.
-
Liquid biopsy for monitoring high-grade glioma using patient-specific DNA junctions
A Mayo Clinic team tests a blood test that looks for unique tumor DNA pieces in glioblastoma patients to monitor disease without frequent scans.
-
Deciphering how a brain cell pH helper influences glioma growth
A study is exploring whether a brain cell pH regulator (Slc4a4) affects the growth and blood vessel changes of malignant glioma to identify new angles for treatment.
-
Predicting how gene therapy spreads in glioblastoma after surgery to improve treatment coverage
This project uses a gene therapy that helps radiation work better against glioblastoma and builds computer models to predict where the therapy reaches after surgical tumor removal.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.